cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.22297985.v1
title: Advance intervention of recessive ill-conditioned feature: the early-stage design method based on system recessive inheritance

description: In the fusion design process of the system, ill-conditioned features, that are not explicit in previous generation systems, may exhibit to negate the operation of the new-generation system. This type of ill-conditioned feature is termed as the recessive ill-conditioned feature (R-ICF) of the system. It is believed that R-ICF in the fusion design process is attributed to the complex system recessive inheritance mechanism (C-RIM), which is analogical to organism recessive inheritance. In-depth study of the characteristics of C-RIM, it is found that one of the reasons leading to R-ICF is the recessive couplings between parameters of the previous generation of systems. This article proposes screening methods for recessive couplings and preliminary methods to intervene R-ICF. An auxiliary software is developed to facilitate implementation of the currently proposed methods. In order to reduce the number of design iterations due to R-ICF, thus to improve efficiency for the fusion innovation process, this article further proposes a system fusion innovation design process model based on C-RIM. Through this process model, R-ICF incurred by recessive couplings can be detected and resolved in advance at the early-stage of product design. The applicability of the currently proposed process model is demonstrated by design exemplification with an irregular workpiece transport system. <b>Abbreviation:</b> A, Act; C-RIM, complex system recessive inheritance mechanism; Ai,i=1,2,3… Act; DCC, design-centric complexity; EO, Execution object; EOi,i=1,2,3… Execution object; Fi,i=1,2,3… Function; N, Noun; PSS, Product service systems; R-ICF, Recessive ill-conditioned feature; TRIZ, theory of inventive problem solving; R-ICF-n-m R-ICF with <i>n</i>(<i>n</i> ≥ 3) affected function incurred by parameters from <i>m</i> (<i>m</i> ≥ 3) source systems; T, Target; Ti,i=1,2,3… Target; V, Verb
DOI: 10.6084/m9.figshare.22822406
title: Monitoring and characterization of field-evolved resistance to diamide insecticides in <em>Spodoptera litura</em> collected from eastern China

description: The data that support the finding of the study: Monitoring and characterization of field-evolved resistance to diamide insecticides in <em>Spodoptera litura</em> collected from eastern China.
DOI: 10.6084/m9.figshare.8142386
title: Additional file 1: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S1. Summary of read mapping in RNA-Seq analysis of yellow and black rapeseeds. B3, B4, B5, B6 and BM indicate 3 ~â 6 WAF and mature black seed. Y3, Y4, Y5, Y6 and YM indicate 3 ~â 6 WAF and mature yellow seed. (XLSX 34577 kb)
DOI: 10.6084/m9.figshare.8142386.v1
title: Additional file 1: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S1. Summary of read mapping in RNA-Seq analysis of yellow and black rapeseeds. B3, B4, B5, B6 and BM indicate 3 ~â 6 WAF and mature black seed. Y3, Y4, Y5, Y6 and YM indicate 3 ~â 6 WAF and mature yellow seed. (XLSX 34577 kb)
DOI: 10.6084/m9.figshare.8142392
title: Additional file 2: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S2. DEGs identified with black or yellow seed development and between same developmental stages of two rapeseeds. (XLSX 11030 kb)
DOI: 10.6084/m9.figshare.8142392.v1
title: Additional file 2: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S2. DEGs identified with black or yellow seed development and between same developmental stages of two rapeseeds. (XLSX 11030 kb)
DOI: 10.6084/m9.figshare.8142398
title: Additional file 3: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S3. DEGs related to seed development. (XLSX 94 kb)
DOI: 10.6084/m9.figshare.8142398.v1
title: Additional file 3: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S3. DEGs related to seed development. (XLSX 94 kb)
DOI: 10.6084/m9.figshare.8142404
title: Additional file 4: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S4. Up- and downregulated genes among all the developmental stages of yellow- and black-seeded B. napus. (XLSX 25 kb)
DOI: 10.6084/m9.figshare.13385285
title: Identifying cortical specific long noncoding RNAs modified by m<sup>6</sup>A RNA methylation in mouse brains

description: Proper development of the mammalian cerebral cortex relies on precise gene expression regulation. Increasing evidence shows that cortical development is regulated by both mRNAs and long noncoding RNAs (lncRNAs), which also are modified by <i>N</i><sup>6</sup>-methyladenosine (m<sup>6</sup>A). Patterns of m<sup>6</sup>A-methylation in lncRNAs in the developing cortex have not been uncovered. Here we reveal differentially expressed lncRNAs and report stage-specific m<sup>6</sup>A-methylation patterns in lncRNAs expressed in mouse embryonic (E) and postnatal (P) cortices using RNA sequencing (RNA-seq) and methylated RNA immunoprecipitation (MeRIP) sequencing. Many lncRNAs show temporal differential expression, and display genic distribution in the genome. Interestingly, we detect temporal-specific m<sup>6</sup>A-methylation with consensus m<sup>6</sup>A motif GGACU in the last exon in most lncRNAs. And m<sup>6</sup>A methylation levels of lncRNAs are positively correlated with the transcript abundance of lncRNAs that have no significantly differential expression in E- and P-stages. Furthermore, the transcript abundance has a positive correlation between the m<sup>6</sup>A genic lncRNAs and their nearest m<sup>6</sup>A methylated mRNAs. Our work reveals a fundamental expression reference of lncRNAs and their nearest mRNAs, and highlights an importance of m<sup>6</sup>A-mediated epitranscriptomic modifications in lncRNAs that are temporally expressed in the developing cortex.
DOI: 10.6084/m9.figshare.8142404.v1
title: Additional file 4: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S4. Up- and downregulated genes among all the developmental stages of yellow- and black-seeded B. napus. (XLSX 25 kb)
DOI: 10.6084/m9.figshare.8142413
title: Additional file 5 of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S1. The SOM clusters of DEGs from five developmental stages of two rapeseed lines. (XLSX 173 kb)
DOI: 10.6084/m9.figshare.8142413.v1
title: Additional file 5 of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S1. The SOM clusters of DEGs from five developmental stages of two rapeseed lines. (XLSX 173 kb)
DOI: 10.6084/m9.figshare.8142419
title: Additional file 6: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S5. All the up- and down-DEGs with GO annotation. (XLSX 63 kb)
DOI: 10.6084/m9.figshare.8142419.v1
title: Additional file 6: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Table S5. All the up- and down-DEGs with GO annotation. (XLSX 63 kb)
DOI: 10.6084/m9.figshare.8142422
title: Additional file 7: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S2. KEGG enrichment of DEGs (Y3 vs. B3) in flavonoid and phenylpropanoid biosynthesis. (XLSX 24 kb)
DOI: 10.6084/m9.figshare.8142422.v1
title: Additional file 7: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S2. KEGG enrichment of DEGs (Y3 vs. B3) in flavonoid and phenylpropanoid biosynthesis. (XLSX 24 kb)
DOI: 10.6084/m9.figshare.8142425
title: Additional file 8: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S3. KEGG enrichment of up- and down-DEGs between yellow- and black-seeded B. napus. (XLS 31 kb)
DOI: 10.6084/m9.figshare.8142425.v1
title: Additional file 8: of Transcriptomic comparison between developing seeds of yellow- and black-seeded Brassica napus reveals that genes influence seed quality

description: Figure S3. KEGG enrichment of up- and down-DEGs between yellow- and black-seeded B. napus. (XLS 31 kb)
DOI: 10.6084/m9.figshare.21249648
title: Transcript Annotation

description: Basic annotations and summary statistics for transcripts including mRNAs, lncRNAs and circRNAs identified for human and mouse species via ASJA program and CIRI2 software.
DOI: 10.6084/m9.figshare.21249651
title: Mouse Bulk Expression Matrix and Metadata

description: TPM normalized counts and metadata were provided for 17 datasets of mouse bulk liver samples.
DOI: 10.6084/m9.figshare.21249651.v1
title: Mouse Bulk Expression Matrix and Metadata

description: TPM normalized counts and metadata were provided for 17 datasets of mouse bulk liver samples.
DOI: 10.6084/m9.figshare.21249654
title: Human Bulk Expression Matrix and Metadata

description: TPM normalized counts and metadata were provided for 35 datasets of human bulk tissue.
DOI: 10.6084/m9.figshare.21249654.v1
title: Human Bulk Expression Matrix and Metadata

description: TPM normalized counts and metadata were provided for 35 datasets of human bulk tissue.
DOI: 10.6084/m9.figshare.8142479
title: Additional file 1: of Gene expression profiles that shape high and low oil content sesames

description: Table S1. Materials and samples; Table S2. Overview of the generated data; Table S3. The total expressed genes with a RPKM greater than 5; Table S4. The enriched KEGG pathways of the DEGs between HO and LO in the seeds and carpels at different stages; Table S5. The 254 DEGs for more than one stage between HOS and LOAS/LOBS; Table S6. The 79 DEGs for more than one stage between HOC and LOAC/LOBC; Table S7. The 11 upregulated lipid homologous genes; Table S8. The 805 DEGS that appeared in two or more stages between the high and low oil content sesames; Table S9. The enriched GO terms for the 45 lipid homologous genes and 341 co-expressed genes; Table S10. Function annotation of the 23 core DEGs in the seed between the HO and LO sesames; Table S11. Shared and special enriched GO terms in the seeds and carpels; Table S12. Function annotation of the 55 core DEGs in the capsule between the HO and LO sesames. (XLSX 68 kb)
DOI: 10.6084/m9.figshare.8142479.v1
title: Additional file 1: of Gene expression profiles that shape high and low oil content sesames

description: Table S1. Materials and samples; Table S2. Overview of the generated data; Table S3. The total expressed genes with a RPKM greater than 5; Table S4. The enriched KEGG pathways of the DEGs between HO and LO in the seeds and carpels at different stages; Table S5. The 254 DEGs for more than one stage between HOS and LOAS/LOBS; Table S6. The 79 DEGs for more than one stage between HOC and LOAC/LOBC; Table S7. The 11 upregulated lipid homologous genes; Table S8. The 805 DEGS that appeared in two or more stages between the high and low oil content sesames; Table S9. The enriched GO terms for the 45 lipid homologous genes and 341 co-expressed genes; Table S10. Function annotation of the 23 core DEGs in the seed between the HO and LO sesames; Table S11. Shared and special enriched GO terms in the seeds and carpels; Table S12. Function annotation of the 55 core DEGs in the capsule between the HO and LO sesames. (XLSX 68 kb)
DOI: 10.6084/m9.figshare.24968345
title: Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data

description: The burden of diabetes on individuals, healthcare systems, and society must be explored to improve and sustain diabetes care. With this aim, we estimated both past and future diabetes-related direct health expenditures in Slovenia. Analysis of expenditures from the healthcare payer perspective during the 2019–2022 period was based on individual patient data on expenditures for seven groups of diabetes-related medical conditions from the population-level database of the Health Insurance Institute of Slovenia. Expenditure projections were prepared using the European Commission’s methodology for budgetary projections. In the 2019–2022 period, average annual diabetes-related expenditures equaled €174.1 million (€1,108 per patient), with their average annual growth rate reaching 12.5%. Expenditures due to inpatient care (33%) and drugs used in diabetes (24%) had the highest shares. More than half of the expenditures were due to complications of diabetes. The diabetes-related expenditures as a share of GDP are projected to increase by 19.2% from 2019 to 2030, with slower yet continued growth up to 2050. Diabetes-related expenditures in Slovenia continue to rise. By focusing on the prevention and optimal management of diabetes, its impact on the healthcare system could be reduced significantly, given the magnitude of expenditures attributed to complications. Diabetes is a chronic metabolic disease characterized by elevated blood sugar levels, leading to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. The number of patients with diabetes has been increasing and accounted for about 10% of the world’s population aged 20–79 years in 2021. Diabetes and its complications also represent a substantial economic burden for individuals, healthcare systems, and society. Using data extracted from the database of the Health Insurance Institute of Slovenia, we looked at the direct healthcare expenditures related to diabetes over the 2019–2022 period and estimated their future trends. During the observed period, the average annual diabetes-related expenditures from the healthcare payer perspective equaled €174.1 million (€1,108 per patient), with their average annual growth rate reaching 12.5%. Expenditures due to hospitalizations (33%) and drugs used in diabetes (24%) had the highest shares. More than half of the expenditures were due to the complications of diabetes. Diabetes-related expenditures as a share of GDP are projected to increase by 19.2% from 2019 to 2030, with slower yet continued growth up to 2050. Our results confirm the growing economic burden of diabetes in Slovenia. Given that modifiable risk factors significantly contribute to the development of diabetes, primary prevention programs to promote healthy lifestyles need to be strengthened. By improving the detection of diabetes and managing it optimally, the progression of the disease and the occurrence of its costly complications can also be prevented considerably.
DOI: 10.6084/m9.figshare.24968345.v1
title: Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data

description: The burden of diabetes on individuals, healthcare systems, and society must be explored to improve and sustain diabetes care. With this aim, we estimated both past and future diabetes-related direct health expenditures in Slovenia. Analysis of expenditures from the healthcare payer perspective during the 2019–2022 period was based on individual patient data on expenditures for seven groups of diabetes-related medical conditions from the population-level database of the Health Insurance Institute of Slovenia. Expenditure projections were prepared using the European Commission’s methodology for budgetary projections. In the 2019–2022 period, average annual diabetes-related expenditures equaled €174.1 million (€1,108 per patient), with their average annual growth rate reaching 12.5%. Expenditures due to inpatient care (33%) and drugs used in diabetes (24%) had the highest shares. More than half of the expenditures were due to complications of diabetes. The diabetes-related expenditures as a share of GDP are projected to increase by 19.2% from 2019 to 2030, with slower yet continued growth up to 2050. Diabetes-related expenditures in Slovenia continue to rise. By focusing on the prevention and optimal management of diabetes, its impact on the healthcare system could be reduced significantly, given the magnitude of expenditures attributed to complications. Diabetes is a chronic metabolic disease characterized by elevated blood sugar levels, leading to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. The number of patients with diabetes has been increasing and accounted for about 10% of the world’s population aged 20–79 years in 2021. Diabetes and its complications also represent a substantial economic burden for individuals, healthcare systems, and society. Using data extracted from the database of the Health Insurance Institute of Slovenia, we looked at the direct healthcare expenditures related to diabetes over the 2019–2022 period and estimated their future trends. During the observed period, the average annual diabetes-related expenditures from the healthcare payer perspective equaled €174.1 million (€1,108 per patient), with their average annual growth rate reaching 12.5%. Expenditures due to hospitalizations (33%) and drugs used in diabetes (24%) had the highest shares. More than half of the expenditures were due to the complications of diabetes. Diabetes-related expenditures as a share of GDP are projected to increase by 19.2% from 2019 to 2030, with slower yet continued growth up to 2050. Our results confirm the growing economic burden of diabetes in Slovenia. Given that modifiable risk factors significantly contribute to the development of diabetes, primary prevention programs to promote healthy lifestyles need to be strengthened. By improving the detection of diabetes and managing it optimally, the progression of the disease and the occurrence of its costly complications can also be prevented considerably.
DOI: 10.6084/m9.figshare.25196651
title: Meta-analysis of traditional Chinese medicine on chronic kidney disease

description: To explore the effect of traditional Chinese medicine (TCM) on the treatment of chronic kidney disease (CKD). Databases were used for literature research until 16 December 2022, including PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Embase. After full-text screening, data were extracted by two researchers independently. The Cochrane ROB tool was applied for quality assessment. The heterogeneity was tested using the Chi-squared-based Q statistic test and the I<sup>2</sup> statistic. The findings revealed that the use of TCM significantly improved the total effective rate (pooled odds ratio (OR) = 1.35, 95% confidence interval (CI) = [1.15, 1.57]), reduced the serum creatinine (SCr) level (pooled mean difference (MD) = -0.11, 95% CI = [−0.20, −0.03]), and increased the estimated glomerular filtration rate (eGFR, pooled MD = 3.76, 95% CI = [2.66, 4.87]) in patients with CKD, compared with non-TCM treatment. Meanwhile, TCM performed better effect on 24-h proteinuria (pooled MD = 0.17, 95% CI = [0.04, 0.31]) than non-TCM. No significant difference in the incidence of adverse events was found between TCM and non-TCM treatment (pooled OR = 0.63, 95% CI = [0.32, 1.24]). Sensitivity analysis demonstrated the stability of the pooled estimates. TCM has the advantage over non-TCM treatment and is worth popularizing and applying in the prevention and cure of CKD. CRD42021279281
DOI: 10.6084/m9.figshare.25196651.v1
title: Meta-analysis of traditional Chinese medicine on chronic kidney disease

description: To explore the effect of traditional Chinese medicine (TCM) on the treatment of chronic kidney disease (CKD). Databases were used for literature research until 16 December 2022, including PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Embase. After full-text screening, data were extracted by two researchers independently. The Cochrane ROB tool was applied for quality assessment. The heterogeneity was tested using the Chi-squared-based Q statistic test and the I<sup>2</sup> statistic. The findings revealed that the use of TCM significantly improved the total effective rate (pooled odds ratio (OR) = 1.35, 95% confidence interval (CI) = [1.15, 1.57]), reduced the serum creatinine (SCr) level (pooled mean difference (MD) = -0.11, 95% CI = [−0.20, −0.03]), and increased the estimated glomerular filtration rate (eGFR, pooled MD = 3.76, 95% CI = [2.66, 4.87]) in patients with CKD, compared with non-TCM treatment. Meanwhile, TCM performed better effect on 24-h proteinuria (pooled MD = 0.17, 95% CI = [0.04, 0.31]) than non-TCM. No significant difference in the incidence of adverse events was found between TCM and non-TCM treatment (pooled OR = 0.63, 95% CI = [0.32, 1.24]). Sensitivity analysis demonstrated the stability of the pooled estimates. TCM has the advantage over non-TCM treatment and is worth popularizing and applying in the prevention and cure of CKD. CRD42021279281
DOI: 10.6084/m9.figshare.24754374
title: Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial

description: This study aims to conduct a cost-effectiveness analysis of trastuzumab deruxtecan versus chemotherapy for HER2-positive metastatic breast cancer from the perspective of the Chinese healthcare system. A three-state partitioned survival model was constructed to simulate the treatment. The analysis yielded information on the costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses have been carried out to scrutinize the model’s uncertainties The total cost for the trastuzumab deruxtecan group was found to be $228601.57, while the chemotherapy group incurred a total cost of $84901.38. It was found that the trastuzumab deruxtecan group exhibited an incremental gain of 2.95 QALYs in comparison to the chemotherapy group. However, this additional benefit came at an additional cost of $143700.19 for the trastuzumab deruxtecan treatment, calculated in the ICER at $48711.93/QALY, which surpasses the willingness-to-pay threshold of $37304.34/QALY in China. Sensitivity analyses indicated that the results were robust to variations in key parameters and assumptions. Trastuzumab deruxtecan was not a cost-effective treatment option for patients with HER2-positive metastatic breast cancer in China. However, the use of trastuzumab deruxtecan may offer a cost-effective treatment alternative provided that its price is diminished.